Inclinix inks deal with JSW Life Sciences to boost EU patient recruitment
Under the deal, JSW will support the enrolment of all the Wilmington, US-based company’s Phase I-IV studies in the European Union, providing more than 100 enrolment professionals. Inclinix has also opened an office in Graz, Austria.
The firm’s president and CEO Tobin Geatz said the deal is crucial to the business' cross-Atlantic growth, and will boost its global offering.
He said: “As Inclinix has experienced significant growth over the past year, it has been important for us to identify a European partner that shares our philosophy and performance enrolment model.”
Manfred Windisch, CEO of JSW, also said the deal would provide Inclinix with a broader range of communication channels with native speakers.
He added: “We are excited to combine our clinical expertise and native-language teams with Inclinix’s enrolment experience.”
